Evoq Remedies Flags Significant Governance and Financial Risks

Evoq Remedies Ltd has reported a net loss of ₹0.2399 crore on revenue of ₹25.5068 crore for the year ended March 31, 2026.
The company received a qualified opinion from its statutory auditor, with a material uncertainty declared regarding its going concern status.

Reader Takeaway: Qualified audit and going concern uncertainty signal significant financial and governance risks for shareholders.

What just happened

The statutory auditor for Evoq Remedies Limited has issued a qualified opinion for the financial year ended March 31, 2026. This is due to several critical issues including unreconciled debtor balances of ₹3.85 crore, unconfirmed supplier advances totaling ₹12.51 crore, and ₹6.70 crore in short-term loans to related parties without proper approval.

The auditor also flagged a material uncertainty related to the company's ability to continue as a going concern. This is driven by liquidity stress, evidenced by unpaid statutory dues and significant tax demands under litigation amounting to ₹8.43 crore. Furthermore, governance deficiencies like the absence of an internal auditor and non-compliant accounting software compound these concerns.

Why this matters

A qualified audit opinion suggests that the financial statements may not present a true and fair view due to specific accounting issues. The 'material uncertainty related to going concern' is a serious red flag, indicating doubts about the company's ability to operate for the foreseeable future. This could impact its ability to meet obligations and continue business operations.

Furthermore, the company is under active investigation by SEBI regarding the utilization of funds from a Preferential Issue. Potential adverse regulatory outcomes could further jeopardize its financial position.

The backstory

Evoq Remedies is involved in the pharmaceutical sector. The company's share capital stands at ₹24.90 crore.

What changes now

Investors will be closely watching how Evoq Remedies addresses the auditor's qualifications and the going concern issues. The company must implement stronger internal controls, reconcile outstanding balances, and resolve ongoing litigation and regulatory investigations to restore confidence.

Risks to watch

The primary risks include potential adverse findings from the SEBI investigation, the recoverability of large unreconciled debtor and supplier balances, and the company's ability to meet its statutory and litigation-related financial obligations.

Peer comparison

(No peer comparison data available in the filing.)

Context metrics (time-bound)

• Net Loss: ₹(0.2399) crore for the year ended March 31, 2026.
• Revenue from Operations: ₹25.5068 crore for the year ended March 31, 2026.
• Unconfirmed Debtor Balances: ₹3.8546 crore.
• Unconfirmed Supplier Advances: ₹12.5118 crore.
• Related Party Loans: ₹6.7026 crore.
• Unpaid TDS: ₹0.3876 crore.
• Outstanding Income Tax Provision: ₹0.6163 crore.
• GST Demand: ₹6.5503 crore (under litigation).
• Income Tax Demand: ₹1.8792 crore (under litigation).
• SEBI Preferential Issue Investigation Amount: ₹19.21 crore.

What to track next

Investors should track any further communications from SEBI, the company's progress in reconciling its financial discrepancies, and its ability to manage its liquidity and legal challenges.